Dbv Technologies S.A. (DBV)

Overview

DBV Technologies S.A. is a trailblazing clinical-stage biopharmaceutical company based in Montrouge, France, with a focus on the research and development of epicutaneous immunotherapy products. Founded in 2002, the company is committed to pushing the boundaries of medical science to create solutions for some of the most challenging allergic conditions. With an innovative approach that centers on the use of skin as a gateway to safely stimulate the immune system, DBV Technologies aspires to bring new hope to patients suffering from food allergies and other immune-related disorders.

Products and Services

Viaskin Peanut

This leading product from DBV Technologies is an epicutaneous immunotherapy aimed at treating peanut allergies. Having completed Phase 3 clinical trials, Viaskin Peanut represents a pioneering treatment that promises to redefine the approach towards managing peanut allergies, potentially offering a less invasive and more patient-friendly option compared to traditional therapies.

Viaskin Milk

Currently in Phase 1/2 clinical trials, Viaskin Milk is an innovative treatment designed for patients with cow's milk protein allergy (CMPA), including conditions like immunoglobulin E (IgE) mediated allergy and eosinophilic esophagitis. Leveraging the proven Viaskin technology platform, this product aims to provide a novel therapeutic option for managing CMPA, one of the most common food allergies in children.

Earlier Stage Research Programs

DBV Technologies is also pioneering research into vaccines and treatments for a range of other conditions, including respiratory syncytial virus, inflammatory bowel disease, celiac disease, and type 1 diabetes. These early-stage projects highlight the company's commitment to using its expertise in immunotherapy to tackle a broad spectrum of immune-related diseases.

Viaskin Technology Platform

At the heart of DBV Technologies' product pipeline is the Viaskin technology platform, a novel approach to immunotherapy that uses the skin as a portal to deliver allergenic proteins to the immune system without entering the bloodstream. This technique aims to desensitize patients to food allergens, potentially transforming the way food allergies are treated.

Collaboration with Nestlé Health Science

DBV Technologies has entered into a strategic collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of non-IgE mediated cow's milk protein allergy (CMPA) in infants and toddlers. This partnership underscores DBV's dedication to advancing diagnostic solutions and therapeutic interventions for food allergies, expanding its impact beyond treatment to early and accurate diagnosis.